Cardinal Health price target raised to $240 from $230 at BofA

BofA raised the firm’s price target on Cardinal Health (CAH) to $240 from $230 and keeps a Buy rating on the shares after updating the firm’s model to reflect Cardinal’s updated adjusted EPS outlook for FY26. The firm, which remains confident in the trajectory of the core Pharma business and Other segment growth businesses, sees long-term 12-14% adjusted EPS targets as “achievable,” the analyst tells investors.